| Literature DB >> 33495880 |
Connal Robertson-More1, Ted Wu2.
Abstract
BACKGROUND: Concerns regarding the aerosolized transmission of SARS-CoV-2 via SS have caused significant apprehension among surgeons related to the use of minimally invasive surgery (MIS) during the COVID19 pandemic. While a limited number of studies have previously demonstrated the presence of viral material in SS, no comprehensive systematic review exists on the subject of viral transmission in SS. Methods A systematic review of the literature was conducted as per PRISMA guidelines. MEDLINE, EMBASE, and CENTRAL databases were searched for publications reporting the primary outcome of the presence of viral particles in SS and secondary outcomes of indices suggesting transmission of viable virus particles in SS producing clinically important infection. All human, animal, and in vitro studies which used accepted analytic techniques for viral detection were included. A meta-analysis was not complete due to methodologic heterogeneity and inconsistent reporting of outcomes of interest.Entities:
Keywords: Aerosols; COVID19; Infection; Plume; Surgical smoke; Virus
Mesh:
Substances:
Year: 2021 PMID: 33495880 PMCID: PMC7833447 DOI: 10.1007/s00464-020-08261-5
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
Fig. 1PRISMA diagram of study selection in the systematic literature search (Color figure online)
National institutes of health quality assessment case series
| Study | LOE | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|---|
| Abramson et al. 1990 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Akbarov et al. 2013 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Andre et al. 1990 [ | IV | No | No | NR | NR | No | Yes | Yes | N/A | Yes |
| Baggish et al. 1991 [ | III | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Bellina et al. 1982 [ | IV | Yes | No | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Bergbrant et al. 1994 [ | IV | Yes | No | No | NR | Yes | Yes | Yes | N/A | Yes |
| Best et al. 2020 [ | III | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Capizzi et al. 1998 [ | III | Yes | Yes | Yes | NR | Yes | Yes | Yes | N/A | Yes |
| Ediger et al. 1989 [ | III | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Ferenczy et al. 1990 [ | IV | Yes | Yes | No | NR | Yes | Yes | Yes | N/A | Yes |
| Ferenczy et al. 1990 [ | IV | Yes | Yes | No | NR | Yes | Yes | Yes | N/A | Yes |
| Garden et al. 1988 [ | IV | Yes | Yes | No | NR | Yes | Yes | Yes | N/A | Yes |
| Garden et al. 2002 [ | III | Yes | Yes | N/A | NR | Yes | Yes | Yes | N/A | Yes |
| Hagen et al. 1997 [ | III | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Higashi et al. 2017 [ | IV | Yes | No | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Hirota et al. 2018 [ | IV | Yes | No | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Hughes et al. 1998 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Ilmarinen et al. 2012 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Johnson et al. 1991 [ | III | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Kashima et al. 1991 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Kunachak et al. 1996 [ | III | Yes | No | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Kwak et al. 2016 [ | IV | Yes | Yes | NR | No | Yes | Yes | Yes | N/A | Yes |
| Matchette et al. 1991 [ | IV | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Matchette et al. 1993 [ | IV | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Moreira et al. 1996 [ | IV | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Neumann et al. 2018 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Sawchuk et al. 1988 [ | III | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Sood et al., 1994 [ | IV | Yes | Yes | Yes | NR | Yes | Yes | Yes | N/A | Yes |
| Starr et al. 1992 [ | III | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Subbarayan et al. 2019 [ | III | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Taravella et al., 1997 [ | IV | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Taravella et al., 1999 [ | III | Yes | N/A | N/A | N/A | Yes | Yes | Yes | N/A | Yes |
| Weyandt et al., 2011 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Wisniewski et al., 1990 [ | IV | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
| Zhou et al., 2019 [ | III | Yes | Yes | NR | NR | Yes | Yes | Yes | N/A | Yes |
LOE Level of Evidence
1. Was the study question or objective clearly stated?
2. Was the study population clearly and fully described, including a case definition?
3. Were the cases consecutive?
4. Were the subjects comparable?
5. Was the intervention clearly described?
6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants?
7. Was the length of follow-up adequate?
8. Were the statistical methods well described?
9. Were the results well described?
Viral particles in surgical smoke
| Study | Design | Modality | N | Procedure | Virus | Location | Plume | Result positive |
|---|---|---|---|---|---|---|---|---|
| Bellina et al., 1982 [ | IV | CO2 Laser | 3 | GCA | HPV | NM | DNA/ RNA | 0/3 |
| Garden et al., 1988 [ | IVT/IV | CO2 Laser | 11 | PVA | HPV/ BPV | NM | DNA | 3/4 IVT, 2/7 IV |
| Sawchuk et al., 1989 [ | IVT/IV | CO2 Laser + EC | 8 | PVA | HPV | 2 cm from lesion | DNA | 5/8 laser, 4/7 EC |
| Abramson et al., 1990 [ | IV | CO2 Laser | 7 | LPA | HPV | 5–10 mm above lesion | DNA | 0/7 |
| Andre et al., 1990 [ | IV | CO2 Laser | 3 | GCA | HPV | NM | DNA | 2/3 |
| Ferenczy et al., 1990 [ | IV | CO2 Laser | 9 | GCA | HPV | 1–2 cm from field | DNA | 1/9 |
| Wisniewski et al., 1990 [ | IV | CO2 Laser | 10 | GCA + CIN | HPV | 5 cm around lesion | DNA | 0/10 |
| Kashima et al., 1991 [ | IV | CO2 Laser | 30 | LPA | HPV | 2–5 cm from lesion | DNA | 17/30 |
| Sood et al., 1994 [ | IV | EC | 49 | LEEP | HPV | NM | DNA | 18/49 |
| Hughes et al., 1998 [ | IV | Er:YAG Laser | 5 | EVA | HPV | Adjacent laser handpiece | DNA | 0/5 |
| Weyandt et al., 2011 [ | IV | APC, CO2 Laser | 10 | GCA | HPV | NM | DNA | 3/10 |
| Akbarov et al. 2013 [ | IV | Ho:YAG Laser | 66 | GCA | HPV | NM | DNA | 66/66 |
| Neumann et al., 2018 [ | IV | EC | 24 | LEEP | HPV | Adjacent loop EC | DNA | 4/24 |
| Subbarayan et al., 2019 [ | IV | EC | 6 | Transoral SCC | HPV | NM | DNA | 0/6 |
| Zhou et al., 2019 [ | IV | EC | 134 | LEEP | HPV | 2 cm from lesion | DNA | 40/134 |
| Garden et al., 2002 [ | IV | CO2 Laser | 3 | ACA | BPV | 2 cm from lesion | DNA | 3/3 |
| Best et al., 2020 [ | IV | KTP Laser, Coblation | 5 | ACA | MmuPV1 | NM | DNA | 5/5 |
| Kwak et al., 2016 [ | IV | EC | 11 | MIS resection | HBV | 5 mm port | DNA | 10/11 |
| Higashi et al., 2017 [ | EV | EC + HS | 11 | EV ablation | HBV | Semi-closed system | DNA + HBs | 3/5 EC 5/5 HS animal, 8/9 EC 7/9 HS human |
| Hirota et al., 2018 [ | EV | EC + HS | 21 | EV ablation | HBV | Semi-closed system | DNA + HBs | 3/6 EC and HS human, 12 EC 13 HS/15 animal |
| Baggish et al., 1991 [ | IVT | CO2 Laser | 1 | CC | HIV | 1 cm from lesion | DNA | 4/5 samples |
| Johnson et al., 1991 [ | IVT | EC + PT | 27 | CC | HIV | 4–8 inches above | p24 | 0/12 EC, 5/9 router, 1/4 bone saw, 0/2 irrigator |
| Taravella et al., 1997 [ | IVT | Excimer Laser | 4 | CC | VZV | NM | DNA | 3/3 |
IV in vivo, EV ex vivo, IVT in vitro, GCA Genital condylomata ablation, CC in vitro ablation of cell cultures, PVA Plantar verrucae ablation, ACA Animal condylomata ablation, EVA Extremity verrucae ablation, LPA Laryngeal papilloma ablatio, MIS Robotic/Laparoscopic Colorectal/gastric/hepatic, EC electrocautery, HS harmonic scalpel, APC argon plasma coagulation, PT Power Tools, VZV varicella zoster virus, HIV human immunodeficiency virus, HBV hepatitis B virus, LEEP loop electrosurgical excision procedure, NM = not measured
Viable viral particles in surgical smoke with effects showing potential for transmission
| Study | Design | Modality | N | Virus | Protocol | Result |
|---|---|---|---|---|---|---|
| Ferenczy et al., 1990 [ | IV-H | CO2 Laser | 9 | HPV | Swabs from surgeon nasopharynx, eyelids, ears pre- and post-procedure | No HPV DNA found via filter hybridization on surgeon pre/post |
| Ferenczy et al., 1990 [ | IV-H | CO2 Laser | 43 | HPV | Collected swabs from laser crater and 5 cm margin | Small non-significant increase in positive DNA |
| Bergbrant et al., 1994 [ | IV-H | CO2 Laser + EC | 34 | HPV | Swabs from surgeon nasolabial fold, nostril, and conjunctiva pre and post, petri dishes 1 + 2 m from lesion | 2/5 petri dishes + with CO2 laser, nasolabial/nostril swabs + with EC and CO2 Laser |
| Kunachak et al., 1996 [ | IVT-C | CO2 Laser | 10 | HPV | Plume-exposed culture plate, light microscopy for cytopathic changes | 0/10 + for HPV infectivity, 0/10 + for viable virus containing cells |
| Weyandt et al., 2011 [ | IV-H | APC + CO2 Laser | 28 | HPV | Swabs from surgeon nasolabial fold and glasses pre and post, petri dishes 1 + 2 m from lesion | 2/18 petri dishes + , all surgeon swabs - |
| Ilmarinen et al., 2012 [ | IV-H | CO2 Laser | 10 | HPV | Swabs from surgeon and RN masks and gloves pre- and post-procedure | Gloves: 5/5 + surgeon and RN GCA, 1/5 + surgeon and 3/5 + RN LPA. Masks: - |
| Subbarayan et al., 2019 [ | IV-H | EC | 6 | HPV | Swabs from surgical masks, robot arms, suction device | No HPV DNA found on robot arms, suction device, surgical masks |
| Zhou et al., 2019 [ | IV-H | EC | 134 | HPV | 3 pre- and post-LEEP nasal swabs from surgeon | 2/134 positive for HPV DNA |
| Sawchuk et al., 1989 [ | IVT-C | CO2 Laser + EC | NK | BPV | BPV in plume used for infectivity assay of mouse C127 cells* | BPV in plume induced cytopathic changes in cell cultures |
| Wisniewski et al., 1990 [ | IV-A | CO2 Laser | 2 | BPV-2 | Collected ejecta from 5 cm cylinder around lesion, inoculated into 2 BPV naïve calves | 0/5 × 2 positive |
| Garden et al., 2002 [ | IV-A | CO2 Laser | 3 | BPV | Inoculated calf with BPV containing laser plume | 3/3 inoculated sites developed condylomata |
| Best et al., 2020 [ | IV-A | KTP Laser + Coblation | 20 | mmuPV1 | Media exposed to laser plume used to inoculate nude mice | 9/9 KTP, 50% penetrance in Coblation, 100% penetrance in filter wash positive |
| Starr et al., 1992 [ | IVT-C | CO2 Laser | 7 | SIV | Plume-exposed culture plate, light microscopy for cytopathic changes, ELISA for p26 protein | No SIV p26 or cytopathic changes noted |
| Moreira et al., 1996 [ | IVT-C | Excimer Laser | 10 | HSV, Adenovirus | Plume-exposed culture plate, light microscopy for cytopathic changes | 3/4 positive adenovirus, 6/6 HSV |
| Taravella et al., 1997 [ | IVT-C | Excimer Laser | 3 | VZV | Plume-exposed culture plate, light microscopy for cytopathic changes | 0/3 positive for cytopathic effect in cultures |
| Taravella et al., 1999 [ | IVT-C | Excimer Laser | 2 | SPVV** | Plume-exposed culture plate, light microscopy for cytopathic changes | 2/2 positive for cytopathic effect in cultures |
| Hagen et al., 1997 [ | IVT-C | Excimer Laser | 20 | PRV* | Plume-exposed culture plate, light microscopy for cytopathic changes | 0/20 positive |
| Capizzi et al., 1998 [ | IV-H | CO2 Laser | 13 | All comer | Collected CO2 plume for viral cultures | 0/13 positive |
| Ediger et al., 1989 [ | IVT-C | Er:YAG Laser | 7 | φX174 | Plume-exposed culture plate, light microscopy for cytopathic changes | 6/7 positive plaque forming units |
| Matchette et al., 1991 [ | IVT-C | CO2 Laser, APC | 29 | φX174 | Plume-exposed culture plate, light microscopy for cytopathic changes | 9/29 positive CO2 |
| Matchette et al., 1993 [ | IVT-C | CO2 Laser | 8 | φX174 | Plume-exposed culture plate, light microscopy for cytopathic changes | 8/8 positive |
IV-H in vivo human, IVT-C in vitro cell culture, in vivo animal, NM not measured, SPVV Sabin poliomyelitis vaccine virus (**As model for HSV), PRV Pseudorabies virus (* as model for HIV/HSV), φX174 = φX174 bacteriophage, VZV varicella zoster virus, HIV human immunodeficiency virus, HBV hepatitis B virus, HSV herpes simplex virus, SIV simian immunodeficiency virus, APC argon plasma coagulation